Pfizer Oncology Data Presentations at the ESMO 2012 Congress

At the ESMO 2012 Congress, Pfizer Oncology will present the following data:

**Lung Cancer Presentations**

**Crizotinib:**

(Abstract #1266P) Poster Session: Retrospective Study of Clinicopathologic Factors Associated with ALK Rearrangement and Survival Outcome in Chinese Patients with NSCLC. Xu-Chao Zhang. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)


(Abstract #1267P) Poster Session: A Large Retrospective Analysis of Pemetrexed Activity in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib Treatment. Giorgio V. Scagliotti. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)


Crizotinib/Dacomitinib:

(Abstract #1290P) Poster Session: Phase I Trial of Irreversible Pan-ERBB Inhibitor Dacomitinib in Combination with ALK/MET Inhibitor Crizotinib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Pasi A. Jänne. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)

Dacomitinib:


Axitinib:


Renal Cell Carcinoma Presentations

Axitinib:

(Abstract #843P) Poster Session: Axitinib and Everolimus in the Treatment of Sunitinib-Refractory Patients with Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison Analyses. Irina Proskorovsky. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)

(Abstract #811P) Poster Session: Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy. Viktor Grünwald. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)


Sunitinib:


(Abstract #851P) Poster Session: A Phase IV Multicenter Study of the Efficacy and Safety of Sunitinib as First-Line Therapy in Chinese Patients with Metastatic Renal Cell Carcinoma (mRCC). Shu-Kui Qin. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)

(Abstract #815P) Poster Session: Sunitinib Dosing Schedule and Data Collection Timepoints: Impact on Quality of Life Outcomes in Metastatic Renal Cell Carcinoma (mRCC). Andrew G. Bushmakin. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)


(Abstract #848P) Poster Session: Overall Survival in Metastatic Renal Cell Carcinoma (mRCC): A Comparison Between Sorafenib and Best Supportive Care After First Line Treatment with Sunitinib in Sweden. Per Sandström. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)

Temsirolimus:

(Abstract #828P) Poster Session: Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients with Advanced or Metastatic Renal Cell Carcinoma (a/mRCC) in the Usual Health Care Setting. U. Mueller. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)

(Abstract #839P) Poster Session: Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience. L. Ruiz. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)
See Below for Embargo Dates

(Abstract #LBA21_PR) Proffered Papers Session: Randomized Phase IIIb Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from INTORACT. Brian Rini. Monday, October 1, 2012. Session Time: 14:00 – 15:50 CEST. Presentation Time: 14:00 CEST. Location: Hall D. (Embargoed until October 1, 2012 at 14:00 CEST)


Other Presentations

Sunitinib:

(Abstract #1490P) Poster Session: Continued Sunitinib Treatment After Progressive Disease in a Worldwide Treatment-Use Trial of Patients with Gastrointestinal Stromal Tumor (GIST). Peter Reichardt. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. (Embargoed until September 17, 2012)


Temsirolimus: